There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (NASDAQ: EXAS) and SeaSpine Holdings (NASDAQ: SPNE) with bullish sentiments.
Exact Sciences (NASDAQ: EXAS)
In a report released yesterday, Sean Lavin from BTIG reiterated a Buy rating on Exact Sciences (NASDAQ: EXAS), with a price target of $70. The company’s shares closed yesterday at $60.56, close to its 52-week high of $63.60.
Lavin commented:
“5 th , data on Exact Sciences’ second case control study for its liver biomarker is scheduled to be presented at the Digestive Disease Week (DDW) conference. Recall that the biomarkers are being co-developed with the Mayo Clinic. The abstract is available on DDW’s website and preliminary details show encouraging 95% sensitivity across all stages (93% specificity in healthy controls, 86% specificity in cirrhotic controls). A liver screening test is one of a number of platforms in EXAS’ cancer pipeline and given the improving traction here, may be the second real shot on the goal, though years away. While we don’t view this as a material stock-moving event, pipeline advancement is supportive of our positive thesis on the name. We reiterate our Buy rating and $70 PT.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.2% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
Currently, the analyst consensus on Exact Sciences is Strong Buy and the average price target is $66, representing an 9.0% upside.
In a report issued on May 30, Jefferies also maintained a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
SeaSpine Holdings (NASDAQ: SPNE)
BTIG analyst Ryan Zimmerman maintained a Buy rating on SeaSpine Holdings (NASDAQ: SPNE) yesterday and set a price target of $17. The company’s shares closed yesterday at $12.44.
Zimmerman noted:
“and $17 PT We recently traveled with mgmt. of SPNE to investor meetings in the San Francisco area. Nautical phrases aside, we came away encouraged by investor interest and SPNE’s progression towards higher growth in the 2H of FY18. Mgmt. has bolstered the product portfolio and continues to sign up exclusive distributors in key geographies. We also believe SPNE’s orthobiologics business may be underappreciated particularly within the DBM segment. While other segments of biologics may be seeing pressure, SPNE is positioning to be a low cost provider that offers similar efficacy (and handling characteristics) as compared to higher priced biologics ultimately resulting in higher growth both for SPNE and the DBM segment. We maintain our Buy and $17 PT.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 34.0% and a 65.2% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and Globus Medical.
Currently, the analyst consensus on SeaSpine Holdings is Strong Buy and the average price target is $16, representing a 28.6% upside.
In a report issued on May 31, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $16 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
